Intellia Therapeutics, Inc. $NTLA Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 13,010,001 shares of the company’s stock after acquiring an additional 1,965,181 shares during the period. Vanguard Group Inc. owned approximately 11.23% of Intellia Therapeutics worth $116,960,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTLA. Contrarius Group Holdings Ltd lifted its position in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics during the 3rd quarter worth approximately $23,519,000. Farallon Capital Management LLC acquired a new position in Intellia Therapeutics during the 3rd quarter worth approximately $10,486,000. Steadfast Capital Management LP acquired a new position in Intellia Therapeutics during the 3rd quarter worth approximately $6,310,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Intellia Therapeutics by 68.0% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 494,468 shares of the company’s stock worth $8,539,000 after acquiring an additional 200,081 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Down 3.0%

NTLA stock opened at $13.99 on Wednesday. Intellia Therapeutics, Inc. has a 52-week low of $6.83 and a 52-week high of $28.25. The stock’s 50 day moving average is $13.67 and its two-hundred day moving average is $12.15. The company has a market capitalization of $1.69 billion, a PE ratio of -3.95 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 55.63% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. As a group, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -3.5 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on NTLA. KeyCorp set a $25.00 price target on Intellia Therapeutics in a research report on Wednesday, January 28th. Citizens Jmp lifted their price objective on Intellia Therapeutics from $28.00 to $30.00 and gave the stock a “market outperform” rating in a report on Tuesday, April 28th. Wells Fargo & Company lifted their price objective on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and an average target price of $20.36.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.